This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad's Prolaris(R) Test Predicts Risk Of Prostate Cancer Recurrence In Fourth Peer Reviewed Study

SALT LAKE CITY, March 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men who had undergone a radical prostatectomy. The study entitled "Validation of a panel of cell cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," concluded that the Prolaris test effectively stratified men by risk of biochemical recurrence.

Researchers at the University of California, San Francisco, and Myriad Genetics, found that 100% of patients in the study with low-risk Prolaris scores did not have any recurrence of their prostate cancer within the five year study period. However, prostate cancer did recur in 50% of the patients in the study with high-risk Prolaris scores. Importantly, the Prolaris test was found to more accurately predict the risk of prostate cancer recurrence than current clinical parameters used in risk assessment. The authors concluded that the findings may help healthcare providers make better informed decisions regarding treatment of patients following radical prostatectomy.

Following the publication of this study in JCO, Prolaris will have published, peer reviewed data incorporating four major studies and over 1,500 patients. In all four studies, researchers were able to demonstrate the effectiveness of the Prolaris test as a prognostic tool for predicting the risk of recurrence and prostate cancer survival across a variety of tissue formats. Survival and disease recurrence are the gold standard end points for cancer clinical trials and provide the physicians with actionable information that may guide treatment decisions.

"Myriad's Prolaris test is the only test on the market that has consistently demonstrated prognostic value in both pre and post prostatectomy settings," said Jerry Lanchbury Ph.D., Chief Scientific Officer of Myriad Genetics Inc. "The Prolaris test provides physicians and patients with a better risk assessment tool to predict which men are more likely to have recurrence of their disease even after undergoing aggressive treatment such as a radical prostatectomy."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs